JAGUAR HEALTH, INC.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Sep 2023 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M | $2.4M | $2.8M | $2.6M | $2.8M | $3.2M | $869.0K | $1.5M |
| Cost of Revenue | $427.0K | $430.0K | $514.0K | $789.0K | $784.0K | $1.0M | $676.0K | $743.0K |
| Gross Profit | $2.3M | $1.9M | $2.3M | $1.8M | $2.0M | $2.1M | $193.0K | $763.0K |
| Gross Margin | 84.3% | 81.7% | 81.7% | 69.4% | 71.7% | 67.4% | 22.2% | 50.7% |
| Operating Expenses | ||||||||
| Research & Development | $3.7M | $4.3M | $6.1M | $1.9M | $1.5M | $1.4M | $1.6M | $1.4M |
| SG&A Expense | $4.3M | $4.4M | $3.5M | $3.2M | $4.3M | $3.8M | $3.1M | $3.7M |
| Operating Income | $-7.2M | $-8.2M | $-8.8M | $-5.2M | $-5.4M | $-8.5M | $-7.7M | $-5.8M |
| Operating Margin | -264.5% | -349.4% | -312.4% | -200.6% | -193.8% | -266.8% | -880.8% | -386.7% |
| Interest Expense | $-108.0K | $611.0K | $500.0K | $1.5M | $581.0K | $479.0K | $199.0K | $174.0K |
| Pretax Income | $-9.6M | $-9.4M | $-7.9M | $-8.8M | $-7.9M | $-9.2M | $-7.9M | — |
| Income Tax Expense | $0 | $0 | $0 | — | — | — | — | — |
| Net Income | $-9.5M | $-9.2M | $-7.8M | $-8.8M | $-7.9M | $-9.2M | $-7.9M | $-6.0M |
| Net Margin | -348.8% | -392.4% | -276.5% | -340.4% | -283.7% | -291.7% | -913.2% | -395.7% |
| EPS (Basic) | $-0.33 | $-10.89 | $-0.16 | $0.00 | $0.00 | $0.00 | $0.00 | $0.09 |
| EPS (Diluted) | $-0.33 | $-10.89 | $-0.16 | $0.00 | $0.00 | $0.00 | $0.00 | $0.09 |
| Shares Outstanding (Basic) | 28.6M | 1.27B | 49.8M | — | 3.86B | 6.88B | — | — |
| Shares Outstanding (Diluted) | 28.6M | 1.27B | 49.8M | — | 3.86B | 6.88B | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |